| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8133893 | ANGELINI PHARMA | Trazodone and trazodone hydrochloride in purified form |
Mar, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7829120 | ANGELINI PHARMA | Trazodone composition for once a day administration |
Mar, 2027
(3 years from now) | |
Oleptro is owned by Angelini Pharma.
Oleptro contains Trazodone Hydrochloride.
Oleptro has a total of 2 drug patents out of which 0 drug patents have expired.
Oleptro was authorised for market use on 02 February, 2010.
Oleptro is available in tablet, extended release;oral dosage forms.
Oleptro can be used as method of treating depression.
The generics of Oleptro are possible to be released after 13 March, 2029.
Drugs and Companies using TRAZODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 02 February, 2010
Treatment: Method of treating depression
Dosage: TABLET, EXTENDED RELEASE;ORAL
OLEPTRO family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic